{"entity":{"id":"nct05888831","kind":"trial","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05888831 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-06-06 and due to reach its primary completion in 2026-09-30. Interventions recorded: BMS-986449 and Nivolumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05888831","url":"https://clinicaltrials.gov/study/NCT05888831"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05888831","phase":"1/2","setting":"A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","enrolled":100,"outcomes":[]},"route":"/trials/nct05888831/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}